2 results about "Viremia" patented technology

This application relates to the field of biomedical detection technology, specifically to a combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients and its application. The combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients includes one or more of the following biomarkers: TAP1, ISG15, CMPK2, GBP4, OTOF, and SIGLEC1. The biomarker combination provided in this application can objectively and quantitatively reflect the activity of viral replication and the strength of the immune response in the patient, thereby achieving accurate assessment of the severity of viremia. This solves the problem in existing technologies that mainly rely on qualitative or semi-quantitative detection of viral nucleic acids and lack assessment methods closely related to the host's pathological state.

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.